Last reviewed · How we verify
NCT05585827: ePark
Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease
NA trial testing Online cognitive behavioral therapy in Parkinson Disease in 11 participants. Completed in 27 November 2024.
27 November 2024
Quick facts
| Lead sponsor | Helse Stavanger HF |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 7 December 2022 |
| Primary completion | 27 November 2024 |
| Estimated completion | 27 November 2024 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Online cognitive behavioral therapy
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Depressive Symptoms — all drugs for Depressive Symptoms →
- Anxiety — all drugs for Anxiety →
Sponsor
Helse Stavanger HF — full company profile →
Who can join
Adults 35 to 85, any sex, with Parkinson Disease or Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
More than 1 million people in Europe suffer from Parkinson's disease (PD), a brain disorder manifesting with a motor syndrome and several non-motor features. Neuropsychiatric symptoms, like anxiety and depression, are common in patients with PD, and has profound effects on quality of life and activities of daily living of the patient, and caregiver burden. Cognitive behavioral therapy (CBT) has proven efficient for depressive symptoms, but treatment availability to the general patient with PD is low. Thus, there is an urgent need for individualized remote approaches that can be of benefit to patients on a national scale. This study is a remote, randomized delayed start trial of the effectiveness of videoconference based cognitive behavioral therapy (eCBT) for PD patients with depressive symptoms. N=120 participants with PD and depressive symptoms will be recruited from neurological clinics across four health regions in Norway and self-reference, and randomized into two arms: (A) immediate eCBT with concurrent with TAU and (B) a delayed start (14 weeks) of eCBT with TAU alone. Patients will be assessed at baseline before allocation to treatment, with followed up evaluations 14, 28 and 42 weeks after baseline. The trial is designed as a state-of-the-art remote clinical trial, that can be easily implemented existing health services, resulting in a rapid implementation and improvement of treatment for patients with PD, and potentially large translational value to other brain disorders.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The ePark study protocol: A decentralized trial of individual video-assisted cognitive behavioural therapy for depressive disorder in Parkinson's disease.
Erga AH, Alves G, Leentjens AFG. · · 2023 · cited 1× · PMID 36817735 · DOI 10.1016/j.conctc.2023.101080
Verify or expand the search:
- PubMed search for NCT05585827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Online cognitive behavioral therapy
Trials testing the same drug.
- NCT04986969 — Online Cognitive Behavioral Therapy for Depressive Symptoms in Rural Patients with Cardiac Disease · NA · completed
- NCT04995913 — Online Cognitive Behavioral Intervention Program for Hong Kong People With Social Anxiety Disorder · NA · unknown
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Helse Stavanger HF trials
Trials by the same sponsor.
- NCT06983002 — Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Dis · NA · not yet recruiting
- NCT06774261 — Phenserine on the Alzheimer's Treatment Horizon, Study 1 · Phase 1 · not yet recruiting
- NCT06362707 — Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) · Phase 2 · recruiting
- NCT06211907 — Small Macular Holes Treated With Air · NA · recruiting
- NCT06150274 — Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05585827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helse Stavanger HF
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing